DrReddy's Laboratories (RDY)

Overall impact
B (65)

Commentary

DrReddy's Laboratories is a strong overall performer. With a 'B' rating of 65.1 for overall impact (73rd percentile compared to all companies), DrReddy's Laboratories ranks 92nd out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 88 others, and ahead of Evolus, Oyster Point Pharma, Jiangsu Hengrui Medicine and 59 others. On top material causes for DrReddy's Laboratories's industry (Pharmaceuticals & Biotech), DrReddy's Laboratories performs well in Access to Affordable Healthcare (95.9 score), Disaster Readiness and Effective Aid (95.7), Humane Treatment of Animals (89.1) and 1 other cause where it received an 'A' score and performs poorly in Child and Maternal Health (20.0 score), Decent, Safe Work Opportunities (39.3), Accountable Institutions (4.8) and 2 other causes where it received a 'D' or 'F' score.
Impact
Cause RDY
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
27,527
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
India
Share classes
RDY
Description
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation, as well as research and development of differentiated formulations. The company offers its products for various therapeutic categories, which primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, nephrology, vaccines, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Material causes
Ethos considers the following causes material for DrReddy's Laboratories, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.